Cash, Cash Equivalents, and Marketable Securities: Approximately $4 million as of December 31, 2024. Research and Development Expenses: $6.2 million for the year ended December 31, 2024, compared to $10.9 million for the year ended December 31, 2023. General and Administrative Expenses: $13.7 million for the year ended December 31, 2024, compared to $21.1 million
Q: Are you developing the oral semaglutide individually or as a validation tool for other incretins, and how does this align with your capital constraints? A: Our primary focus is on RT-114 due to capital constraints. The semaglutide program, RT-116, is a discovery program used to validate delivery of incretins, showing 107% bioavailability. We are
Q: To what degree should we expect most of the revenue growth being in the second half due to the government’s inability to issue new program start contracts until a final budget is put into place? A: Thomas Krywe, Interim CFO, explained that the growth in the second half is largely due to the flow
Research and Development Expenses (Q4 2024): $6 million, up from $4 million in Q4 2023. Research and Development Expenses (Full-Year 2024): $19.4 million, up from $16.5 million in 2023. Net Loss (Q4 2024): $12.1 million, compared to $6.7 million in Q4 2023. Net Loss (Full-Year 2024): $62.3 million, compared to $27.0 million in 2023. Stock
Total Revenue: $150 million for the year ended December 31, 2024, up from $58.7 million in 2023. Revenue from Collaborative and Other Agreements: $118.9 million. MARGENZA Net Sales: $16.4 million. Contract Manufacturing Revenue: $13.1 million. Research and Development Expenses: $177.2 million, up from $166.6 million in 2023. Selling, General, and Administrative Expenses: $71 million, up
CARGO Therapeutics (CRGX, Financials) saw its stock jump 18.9% pre-market to $4.52 on Wednesday after announcing it would suspend development of its CRG-023 product and allogeneic platform, along with cutting approximately 90% of its workforce to preserve cash and seek a strategic business combination. The decision follows the company’s discontinuation of the Phase 2 FIRCE-1
Net Loss: $11.4 million for Q4 2024, compared to $7.8 million in Q4 2023. R&D Expenses: $9.3 million in Q4 2024, up from $6.5 million in Q4 2023. G&A Expenses: $2.9 million in Q4 2024, compared to $2.4 million in Q4 2023. Cash, Cash Equivalents, and Marketable Securities: $107.6 million as of December 31, 2024.
Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in
Cash Equivalents and Marketable Securities: $245 million as of December 31, 2024, down from $314 million as of December 31, 2023. R&D Expenses: $209 million for the year ended December 31, 2024, compared to $232 million in 2023. Net Proceeds from Public Offering: $131 million received from an upsized public offering of common stock and
Cash, Cash Equivalents, and Marketable Securities: $134.6 million at the end of 2024. Net Cash Used in Operating Activities: $19.3 million for Q4 2024, down from $32 million in Q4 2023. Collaboration Revenue: $16.4 million for Q4 2024, up from $10.7 million in Q4 2023. Research & Development Expenses: $22.3 million for Q4 2024, compared